. Which the company will sign the share purchase agreement on July 24, 2019. Details of such items appear in Attachment 1: Information Memorandum Concerning the Disposition of Assets Please be informed
improved following on-going cost optimization and FY17 guidance maintained. AIS reported 3Q17 EBITDA of Bt17,589mn, +15% YoY and +2.8% QoQ, mainly due to revenue growth and controlled SG&A. YTD, AIS spent
processes, including effectively controlled in maintenance cost. Net gain (loss) on exchange rate Q1-2020 Q1-2019 THB Mn THB Mn THB Mn % Net gain (loss) on exchange rate 112.2 (28.3) 140.5 N.A. (>100) Change
debt obligations. 2. Disclosure of compensation a. Issuer’s directors are on an individual basis; and b. Issuer’s senior managements are on lump sum basis. C. Share Ownership Provide current information
Checklist คุณสมบัติตามเกณฑ์ share swap
decreased by -8.4% YoY. 9M23 EBITDA increased by 4.2% YoY as a result of an improvement in core service revenue and well- controlled SG&A. The net profit closed at Bt22,084mn, surging 18% YoY driven by
be a potential market in the future. For Medical Devices; There is still intense competition in both domestic and foreign markets. Market leaders use price strategies to gain market share. But the
controlled on the selling and administrative expenses. Please be informed accordingly. Sincerely yours, (Unyarat Pornprakit) Director and Chief Executive Officer